Figure 1: Oncogene Her2/neu-initiated, Akt-mediated p21 Cip1/WAF1 inactivation as a suppressor of tumour growth and the cell cycle.

For this study, the researchers focused on vesicles produced in the brain that carry proteins involved in insulin sensitivity ...

AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, providing a new targeted therapy option that significantly increases ...

Capivasertib, developed by AstraZeneca, targets the AKT protein, a molecule known to fuel the multiplication of cancer cells. By inhibiting AKT's action, the drug effectively slows or halts the ...

3-phosphoinositide-dependent protein kinase 1; PKB/AKT, protein kinase B; S6K, ribosomal protein S6 kinase.) However, the discovery of the way in which 'primed' substrates dock with GSK3 might ...

or the loss of a tumor-suppressing protein called PTEN. "Up to 25–40% of BC cases exhibit variations that hyperactivate the PI3K/Akt/mTOR pathway, underscoring its critical role in oncogenesis." ...